{
  "denotations": [
    {
      "id": "T1",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 70,
        "end": 102
      }
    },
    {
      "id": "T2",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 105,
        "end": 109
      }
    },
    {
      "id": "T4",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 168,
        "end": 172
      }
    },
    {
      "id": "T5",
      "obj": "Chemical",
      "span": {
        "begin": 112,
        "end": 138
      }
    },
    {
      "id": "T6",
      "obj": "Chemical",
      "span": {
        "begin": 141,
        "end": 144
      }
    },
    {
      "id": "T3",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 112,
        "end": 127
      }
    },
    {
      "id": "T9",
      "obj": "Disease",
      "span": {
        "begin": 168,
        "end": 193
      }
    },
    {
      "id": "T10",
      "obj": "Chemical",
      "span": {
        "begin": 70,
        "end": 138
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "23407558_2",
  "text": "BACKGROUND : Development of acquired resistance limits the utility of epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitors ( TKI ) for the treatment of EGFR -mutant lung cancers ."
}
